Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301143 | 0.90 | FGFR3 (0.43) | FGFR3KDREGLN2DDB1CRBN | |
| SCHEMBL4058872 | 0.89 | EGLN2 (0.40) | FGFR3KDREGLN2ATMNR1H2 | |
| SCHEMBL4233651 | 0.87 | PTGES (0.38) | EGLN2NR1H2 | |
| SCHEMBL4300649 | 0.84 | GRM5 (0.44) | EGLN2NR1H2RIPK2 | |
| SCHEMBL4297692 | 0.84 | GRM5 (0.36) | EGLN2 | |
| SCHEMBL4301158 | 0.81 | PTGES (0.36) | KDREGLN2NR1H2RIPK2 | |
| SCHEMBL4056602 | 0.81 | FGFR3 (0.39) | FGFR3KDRNR1H2 | |
| SCHEMBL4303398 | 0.80 | CNR2 (0.38) | EGLN2NR1H2 | |
| SCHEMBL4241713 | 0.79 | FGFR3 (0.38) | FGFR3NR1H2 | |
| SCHEMBL4055209 | 0.79 | GABRG2 (0.43) | EGLN2NR1H2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | FGFR3 505/4885KDR 2590/4885EGLN2 1097/4885 |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | FGFR3 505/4885KDR 2590/4885EGLN2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.